Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 399 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Testosterone Clear all

Conditions: Multiple Sclerosis
Interventions: Androgel 10 grams of gel containing 100 mg of testosterone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypogonadism
Interventions: Jatenzo Oral Product; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 27
States / cities: Tempe, Arizona • Lincoln, California • Long Beach, California + 23 more

Conditions: Adolescent Depression
Interventions: Healthy Minds Program; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 11 Years to 14 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Multiple Sclerosis, Erectile Dysfunction, Testosterone Deficiency
Interventions: XYOSTED 75 milligram (mg) in 0.5 ML Auto-Injector; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Prostate, Cancer, Hormonal Cycling
Interventions: GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Opioid Use, Androgen Deficiency, Back Pain
Interventions: Testosterone Cypionate, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sex Disorders
Interventions: testosterone enanthate, duastride; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 21 Years to 40 Years · Male only
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Testosterone Deficiency
Interventions: Men presenting with low-T; Diagnostic Test
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 19 participants
Timeline: 2017
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Muscular Weakness, Sexual Behavior, Quality of Life
Interventions: Formula 1, Formula 2, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Hypogonadism, Malignant Urinary System Neoplasm, Urinary System Disorder, Urinary System Neoplasm
Interventions: Best Practice, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate; Other · Procedure · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Seizure Disorder, Hypogonadism, Erectile Dysfunction
Interventions: Anastrozole 1mg, Placebo Oral Tablet; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Obesity, Insulin Resistance
Interventions: Anastrazole, Testosterone, Dutasteride, GnRH antagonist; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 24 Years to 51 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: San Diego, California

Conditions: Hypogonadism
Interventions: Testosterone enanthate auto-injector; Combination Product
Lead sponsor: Antares Pharma Inc.; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 20
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 17 more

Conditions: Wellness, Health
Interventions: Geranylgeraniol 300 mg, Placebo; Dietary Supplement
Lead sponsor: Designs for Health; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Palm Coast, Florida

Conditions: Sleep Restriction
Interventions: Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 60 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Hypogonadism, Hypogonadotropic, Obesity
Interventions: anastrozole (1 mg/day), Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypogonadal Males
Interventions: Testosterone Gel (FE 999303); Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Hypogonadism
Interventions: TSX-002; Drug
Lead sponsor: TesoRx Pharma, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Eovist; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Contraception, Hypogonadism
Interventions: Oral Testosterone, Leuprolide (Lupron), Dutasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Spinal Cord Injury
Interventions: Testosterone Gel applied by a pump, Stand Training, Electrical Stimulation; Drug · Other · Device
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 58 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Depressive Disorder, Major
Interventions: Testosterone gel, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Hypogonadism
Interventions: Testosterone MD-Lotion; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Tuscon, Arizona • Burbank, California • New Britain, Connecticut + 1 more

Conditions: Prostate Cancer
Interventions: Degarelix acetate, Leuprolide acetate; Drug
Lead sponsor: Urology of Virginia; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Virginia Beach, Virginia

Search by objective public record fields.

Testosterone Treatment for Multiple Sclerosis

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

Adolescent Mood During Puberty and Testosterone

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)

The Effect of 5-Alpha Reductase on Testosterone in Men

Evaluation of Prealbumin Levels in Men With Low-T

Supplement Study: Strength, Testosterone, Sexual Function, Quality of Life

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

Metabolic Effects of Steroids in Obese Men

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

A Crossover Clinical Trial Investigating the Effects of Geranylgeraniol (GG) Supplementation on Testosterone Levels in Healthy Men and Women Over an 18-week Period

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator

Oral Testosterone for the Treatment of Hypogonadism

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations

Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide